Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Prolymphocytic, B-Cell 3Lymphoma 2Leukemia, B-Cell 2

Interventions

Cyclophosphamide 18ofatumumab 14fludarabine 12Rituximab 11ibrutinib 10fludarabine phosphate 9acalabrutinib 7obinutuzumab 6Lenalidomide 6Bendamustine Hydrochloride 6venetoclax 5pirtobrutinib 4Vincristine 4Mesna 4Melphalan 4Immunotherapy, Adoptive 4Whole-Body Irradiation 3Mycophenolic Acid 3Chlorambucil 3Bortezomib 3Alemtuzumab 3spebrutinib 2navitoclax 2idelalisib 2Tacrolimus 2Tablets 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2KW-2478 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, B-Cell × Antigens, CD19 × Clear all
NCT04648475 2023-04-18

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Chongqing Precision Biotech Co., Ltd

Phase 1/2 Unknown
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT04649983 2023-04-18

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Chongqing Precision Biotech Co., Ltd

Phase 1/2 Unknown
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡